Study finds COI in guideline panels

Share this article:

Researchers evaluating diabetes and high cholesterol screening and treatment guidelines found that guideline-panel members are pervaded by financial conflicts of interest.

They evaluated 14 guidelines published by national organizations in the US and Canada between 2000 and 2010. Overall, 150 (52%) of the panel members had COI, of which 138 were declared, the researchers wrote in BMJ. Among panels with chairs, half of these had COI. Panel members from government-sponsored guidelines were less likely to have COI compared with guidelines sponsored by non-government sources—15/92 (16%) vs. 135/196 (69%).

The data “may raise questions about the independence and objectivity of the guideline development process in the United States and Canada,” wrote the authors.

They note that the limited COI among government-sponsored guideline panel members “suggests that expert panels without many COI can be convened.”

COI was defined as direct compensation of a guideline panelist by a manufacturer of a drug used to treat the guideline's disease of interest, in the form of grants (including research), speakers' fees, honorariums, consultant/adviser/employee relationships and stock ownership.

In arguing for only conflict-free panels, an accompanying editorial noted that, while money from drug companies is the “oxygen on which the academic medical world depends,” a change of culture is needed.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?